

## REMARKS


Claims 25-33, 35-37 39-45 and 47 are currently pending in the application. Claims 32 and 44 have been amended. The paragraph bridging pages 5 and 6 of the specification has been amended. The forgoing amendments are made to more clearly state the subject matter being claimed.

The amendments are necessary to correct three typographical errors in which the term "CPT111" was recited where "CPT-11" should have been recited. It is well-known within the scientific cancer community that CPT-11 refers to irinotecan which is a water soluble derivative of camptothecin and is used therapeutically as an anti-cancer agent. Please note that the use of the term "CPT111" is among the recitation of a number of other agents well known for having anti-cancer activities. The term "CPT111" is not associated with any known agent or therapeutic utility within the scientific cancer community.

Applicants request the entry of the changes in the specification and claims requested above. Support for the amendments to the claims can be found in the paragraph bridging pages 5 and 6 of the specification as filed and now amended. No new matter has been added by the amendments to the specification or the claims.

If for any reason an additional fee is required, a fee paid is inadequate or credit is owed for any excess fee paid, you are hereby authorized and requested to charge Deposit Account No. **04-1105**.

Respectfully submitted,

  
\_\_\_\_\_  
Gregory B. Butler, PhD (Reg. 34,558)  
EDWARDS & ANGELL, LLP  
P.O. Box 9169  
Boston, MA 02209  
(617) 439-4444

Date: July 27, 2005

499949v1